Trillium Diagnostics Sold to Vivione Biosciences
Vivione Biosciences Inc. is to acquire all of the capital stock of Trillium Diagnostics for US$1.5 million in cash and US$4 million in common shares of Vivione at closing along with subsequent milestone-related.
Trillium is involved in the emerging area of immune-profiling that brings the approach of personalized medicine to infectious disease and sepsis diagnostics.Trillium's lead product, Leuko64, is a quantitative test for neutrophil CD64 expression, a marker directly associated with sepsis diagnosis.
Date Published: February 3, 2015
Source article link: Vivione Biosciences » company contact details
First Ultra-Rapid Phenotypic MRSA/MSSA Differentiation Assay
Battling Antibiotic Resistance - QuickFISH Could Help
Study Results on T2Bacteria Panel for Sepsis from Whole Blood
Momentum Bioscience’s New R&D Facility Opened by David Cameron
EFK Introduces Specific Marker for Early Sepsis Detection